ATR
HealthcareAptarGroup, Inc. · Medical - Instruments & Supplies · $7B
What is AptarGroup, Inc.?
AptarGroup is a global provider of dispensing, sealing, and material science solutions serving the pharmaceutical, beauty, personal care, and food and beverage industries. Headquartered in Crystal Lake, Illinois, the company ships products to customers across North America, Europe, Asia, and Latin America.
AptarGroup generates revenue across three business segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment supplies drug-delivery components such as nasal pumps, metered dose inhaler valves, and injectable packaging. The Beauty + Home segment sells pumps, aerosol valves, and closures to personal care and home care brands. The Food + Beverage segment provides dispensing closures and spray pumps to consumer packaged goods companies. Customers access these products through AptarGroup's direct sales force and a network of independent distributors worldwide.
AptarGroup was incorporated in 1992 and began operating as an independent public company in 1993, with its headquarters in Crystal Lake, Illinois.
- Nasal and respiratory drug-delivery pumps for pharmaceutical markets
- Metered dose inhaler valves for asthma and COPD treatments
- Elastomeric components for injectable primary packaging
- Aerosol valves, closures, and pumps for beauty and personal care
- Dispensing and sealing closures for food and beverage brands
Is ATR a Good Stock to Buy?
UQS Score rates ATR as Below Average overall, reflecting a mixed profile across its five quality pillars.
The Risk pillar registers as Neutral, suggesting the business does not carry outsized financial or operational hazards relative to sector peers. Quality and Moat also land at Neutral, indicating a stable but undifferentiated competitive position in its packaging and dispensing niche.
Growth is the weakest pillar in ATR's profile, pointing to limited near-term revenue and earnings expansion. Valuation is Neutral, meaning the stock does not appear to offer a clear discount to compensate for the subdued growth outlook.
Pro members can view the exact pillar breakdown and the underlying financial metrics driving each score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ATR pay dividends?
Yes — AptarGroup, Inc. pays a dividend.
AptarGroup pays a regular dividend, which is relatively uncommon among mid-cap healthcare-adjacent companies. The consistent payout reflects the company's stable, recurring revenue from long-term supply relationships with consumer and pharmaceutical brands. Income-oriented investors may find the dividend meaningful, though the Growth pillar's Weak rating suggests dividend growth may be constrained in the near term.
When does ATR report earnings?
AptarGroup reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Neutral Quality and Risk ratings suggest results have been broadly stable without significant surprises in either direction. The Weak Growth pillar indicates top-line and earnings expansion has lagged sector peers in recent periods.
For the most recent quarter's results and upcoming reporting dates, visit AptarGroup's investor relations page directly.
ATR Price History
-8.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in AptarGroup, Inc.?
Based on AptarGroup, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ATR Long-term Outlook
ATR's fundamental outlook is shaped primarily by its Weak Growth pillar, which suggests the company faces headwinds in accelerating revenue across its three segments. The Neutral Risk profile provides some reassurance that near-term financial stability is not a primary concern. Longer-term, AptarGroup's partnerships in recycled materials and digital respiratory therapies could open incremental growth avenues, though these are not yet reflected in the Growth pillar rating. The Neutral Valuation label implies the market is pricing in a moderate, rather than optimistic, trajectory.
Growth drivers
- Expanding pharmaceutical drug-delivery demand, particularly in respiratory and injectable categories
- Strategic partnership with PureCycle Technologies targeting sustainable dispensing materials
- Cross-segment exposure to resilient consumer staples and healthcare end markets
Key risks
- Weak Growth pillar signals limited near-term revenue acceleration across all three segments
- Competitive pressure in commodity-adjacent packaging from lower-cost global suppliers
- Neutral Valuation leaves limited margin of safety if growth disappoints further
ATR vs Peers
AptarGroup operates in a broad healthcare and consumer packaging space, where it competes with companies focused on medical devices, drug delivery, and specialty components.
Bausch + Lomb focuses on eye health products and surgical devices, giving it a more concentrated pharmaceutical end-market exposure than AptarGroup's diversified packaging approach.
Masimo specializes in non-invasive patient monitoring technology, competing with AptarGroup only at the intersection of connected health and drug delivery innovation.
Repligen supplies bioprocessing components to biopharmaceutical manufacturers, overlapping with AptarGroup's injectable packaging segment while serving a more specialized customer base.
Frequently Asked Questions
What does AptarGroup do?
AptarGroup designs and manufactures dispensing, sealing, and material science solutions for pharmaceutical, beauty, personal care, and food and beverage companies. Its three segments — Pharma, Beauty + Home, and Food + Beverage — serve customers across North America, Europe, Asia, and Latin America through a direct sales force and distributor network.
Does ATR pay dividends?
Yes, AptarGroup pays a regular dividend. The company's stable, recurring revenue from long-term customer relationships in consumer and pharmaceutical markets supports the ongoing payout. Investors should check AptarGroup's investor relations page for the current dividend rate and payment schedule.
When does ATR report earnings?
AptarGroup reports financial results on a quarterly cadence, in line with standard US-listed company practice. For the exact dates of upcoming earnings releases, refer to the investor relations section of AptarGroup's official website.
Is ATR a good stock to buy?
UQS Score rates ATR as Below Average, driven largely by a Weak Growth pillar alongside Neutral ratings across Quality, Moat, Risk, and Valuation. Whether it fits a portfolio depends on individual goals and risk tolerance. Pro members can access the full pillar breakdown to inform their own assessment.
Is ATR overvalued?
ATR's Valuation pillar is rated Neutral, suggesting the market is pricing the stock in line with a moderate fundamental outlook rather than at a clear premium or discount. Given the Weak Growth rating, the Neutral valuation leaves limited buffer if business momentum does not improve.
How does ATR compare to its competitors?
AptarGroup's diversified exposure across pharma packaging, beauty, and food and beverage sets it apart from more focused peers like Masimo in patient monitoring or Repligen in bioprocessing. Its broad end-market reach provides revenue stability, though the Weak Growth pillar suggests peers with stronger growth profiles may be outpacing it on expansion.
What is ATR's market cap bracket?
AptarGroup is classified as a mid-cap company. This places it in a segment of the market that typically offers more liquidity than small-caps while carrying more growth uncertainty than large-cap peers in the healthcare and packaging space.
Who founded AptarGroup?
AptarGroup was incorporated in 1992 and became an independent public company in 1993. Founding and leadership history is publicly documented and available through AptarGroup's official corporate history and investor relations materials.
Is ATR a long-term quality investment?
As a long-term quality indicator, ATR's UQS Score of Below Average reflects current limitations, particularly in the Growth pillar. The Neutral Risk and Quality ratings suggest the business is operationally stable, but investors seeking long-term compounding may want to monitor whether growth trends improve before committing. The full pillar detail is available to Pro members.
What is the main competitive advantage of AptarGroup?
AptarGroup's Moat pillar is rated Neutral, indicating a moderate rather than wide competitive advantage. Its strength lies in deep customer integration — packaging and dispensing components are often co-developed with brand owners, creating switching costs. The company's material science expertise and pharmaceutical regulatory approvals also raise barriers for new entrants in the Pharma segment.
What sector does ATR belong to?
AptarGroup is classified in the Healthcare sector, primarily due to its significant Pharma segment supplying drug-delivery components. However, the company also has meaningful exposure to consumer staples through its Beauty + Home and Food + Beverage segments, giving it a hybrid defensive character.
Is ATR a growth stock or value stock?
Based on UQS pillar labels, ATR leans neither clearly toward growth nor value. The Growth pillar is Weak, ruling out a strong growth-stock characterization, while the Neutral Valuation pillar means it does not screen as a deep-value opportunity either. It sits in a middle ground more consistent with a stable income-oriented holding.
Unlock Full ATR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare ATR against sector peers on quality dimensions
- ✓See Growth and Valuation detail behind the Weak and Neutral labels
- ✓Get the complete analyst-style breakdown in one view
Pro Analysis
ATR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 43.2 | 49.5 | 40.0 | 23.2 | 55.1 | 52.9 | -0.2 |
| May 22, 2026 | 43.4 | 49.5 | 40.0 | 23.2 | 55.1 | 53.9 | -0.1 |
| May 21, 2026 | 43.5 | 49.5 | 40.0 | 23.2 | 55.1 | 54.7 | -0.1 |
| May 20, 2026 | 43.6 | 49.5 | 40.0 | 23.2 | 55.1 | 55.4 | +0.3 |
| May 19, 2026 | 43.3 | 49.5 | 40.0 | 23.2 | 55.1 | 53.7 | -0.1 |
| May 17, 2026 | 43.4 | 49.5 | 40.0 | 23.2 | 55.1 | 54.2 | 0.0 |
| May 16, 2026 | 43.4 | 49.2 | 40.0 | 23.2 | 55.1 | 54.6 | 0.0 |
| May 14, 2026 | 43.4 | 49.2 | 40.0 | 23.2 | 55.1 | 54.3 | -0.1 |
| May 13, 2026 | 43.5 | 49.0 | 40.0 | 23.2 | 55.1 | 55.3 | +0.2 |
| May 12, 2026 | 43.3 | 49.0 | 40.0 | 23.2 | 55.1 | 54.5 | 0.0 |
ATR — Pillar Breakdown
Quality
— 49.5/100 (25%)AptarGroup, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 23.2/100 (20%)AptarGroup, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 55.1/100 (15%)AptarGroup, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 54.1/100 (15%)AptarGroup, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 40/100 (25%)AptarGroup, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ATR.
Score Composition
Financial Data
More Stock Analysis
How is the ATR UQS Score Calculated?
The UQS (Unified Quality Score) for AptarGroup, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses AptarGroup, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether AptarGroup, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.